Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Completed × LB100 × Clear all

Phase

Status

Recruiting 1 Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Interventions

Paclitaxel 257 Cisplatin 233 Gemcitabine 229 Carboplatin 221 Cyclophosphamide 201 Radiotherapy 197 Irinotecan 166 Bevacizumab 153 pembrolizumab 148 Docetaxel 148 Capecitabine 132 Nivolumab 127 Fluorouracil 117 Dexamethasone 111 Bortezomib 109 Erlotinib Hydrochloride 107 Oxaliplatin 105 Sorafenib 103 Cytarabine 103 Temozolomide 97 Rituximab 96 Leucovorin 95 Doxorubicin 95 Etoposide 94 Filgrastim 93 Lenalidomide 86 Everolimus 85 Pemetrexed 81 Ipilimumab 78 fludarabine phosphate 74

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01837667 2017-01-24

Phase I Study of LB-100 With Docetaxel in Solid Tumors

Lixte Biotechnology Holdings, Inc.

Phase 1 Completed

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡